Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
148.89 K
Value Traded
52.82 K
Short % Float
2.77%
Days to Cover
2.3
-13.94%Week
-35.18%1 Month
-54.82%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.70 M
EPS (TTM)
-0.54
P/E Ratio
-
Ent. Value
-188.48 K
Total Shares
22.33 M
Float Shares
24.34 M
Insiders
2.22%
Institutions
6.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RKTO Catalyst Timeline
Dated clinical, regulatory and corporate events for Rocket One Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rocket One Inc.
100Total events
6Upcoming
31Tier-1 (high impact)
2019 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Trial Stopped EfficacyHT-001Trial
Phase 2a trial of HT-001 ended early following strong interim efficacy results
dermatologic toxicities associated with EGFR inhibitor cancer therapiessource ↗
▲Interim Efficacy DataHT-001Clinical Data
Strong interim efficacy results from Phase 2a trial of HT-001
dermatologic toxicities associated with EGFR inhibitor cancer therapiessource ↗
▲Partnership / LicenseCorporate
Rocket One signs sponsored research agreement with Virginia Commonwealth University for magnetic computing device development
▲AcquiredCorporate
Rocket One signs definitive agreement to acquire Tracer Drone Technologies
▲Management ChangeCorporate
Appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
▲Partnership / LicenseCorporate
Exclusive license of nanomagnetic AI chip technology from Virginia Commonwealth University
◆Preclinical PoCHT-VAPreclinical
Initial Results from Preclinical Studies
Obesity and Metabolic Healthsource ↗
●IND Enabling CompleteHT-KITPreclinical
Initiate Final Animal Toxicology Studies and Manufacture Clinical Batches
Mast-Cell Derived Cancerssource ↗
◆Full ResultsHT-001Clinical Data
Full Data Set for Open Label PK Cohort
Cutaneous Toxicities associated with EGFR Inhibitorssource ↗
◆Full ResultsHT-001Clinical Data
Full data set for open label PK cohort
Cutaneous Toxicities Associated with EGFR Inhibitorssource ↗
●EU MAA SubmissionHT-001Ex-US Regulatory
Submission to EMA for Clinical Trial Expansion in EU
EGFR Inhibitor Skin Toxicitysource ↗
▲Trial InitiationHT-001Trial
Phase 2a study (CLEER-001) ongoing
EGFR inhibitor induced cutaneous toxicitiessource ↗
▲Primary Endpoint MetHT-001Clinical Data
100% of patients achieved primary efficacy endpoint in Phase 2a
EGFR inhibitor induced cutaneous toxicitiessource ↗
▲Interim AnalysisHT-001Trial
Positive interim data from open-label portion of CLEER-001 Phase 2a trial
pruritus associated with skin toxicities caused by EGFR inhibitorssource ↗
▲Interim AnalysisHT-001Trial
Positive Initial Interim Open Label PK Cohort Data Results
EGFR Inhibitor Skin Toxicitysource ↗
●Manufacturing MilestoneHT-KITCMC / Inspection
GLP animal studies and GMP API manufacturing initiation target
Mast-Cell Derived Cancerssource ↗
▲Partnership / LicenseHT-VACorporate
Obtained License Agreement from Veteran's Affairs for HT-VA
Obesitysource ↗
◆Enrollment UpdateHT-001Trial
All clinical sites active and enrolling in open label and double-blind randomized cohorts
Cutaneous Toxicities Associated with EGFR Inhibitorssource ↗
●Enrollment UpdateHT-001Trial
All Clinical Sites Active and Enrolling in Open Label and Double-Blind Randomized Cohorts
Cutaneous Toxicities associated with EGFR Inhibitorssource ↗
▲Patent GrantedHT-ALZIP / Competition
US Patent Office Awarded HT-ALZ Patent
Alzheimer's Diseasesource ↗
▼Equity OfferingCorporate
Issuance of new warrants exercisable at $1.50 per share, expiring July 3, 2028
●IND Enabling CompleteHT-KITPreclinical
IND-Enabling Animal Toxicology Studies Initiated
Mast-Cell Derived Cancerssource ↗
●Pre IND MeetingHT-KITFDA Meeting
Pre-IND Meeting with FDA and Strategy Confirmed
Mast-Cell Derived Cancerssource ↗
◆Trial InitiationHT-001Trial
HT-001 Phase 2a clinical trial targeted for Q1 2023
Cutaneous Toxicities Associated with EGFR Inhibitorssource ↗
▲First Patient DosedHT-001Trial
Initiated Phase 2a Clinical Trial in Open Label Cohort
Cutaneous Toxicities associated with EGFR Inhibitorssource ↗
▲Enrollment CompleteBioLexaTrial
Open Label dosing portion of Phase 1b Study is completed
Atopic Dermatitissource ↗
▲Trial CompletionBioLexaTrial
Open label dosing portion of Phase 1b study completed
Atopic Dermatitissource ↗
◆Enrollment CompleteTrial
BioLexa Cohort 2 enrollment and dosing expected to conclude Q3 2022
Mild to Moderate Atopic Dermatitissource ↗
◆Interim AnalysisTrial
BioLexa Cohort 2 interim review (n=7) target for May 2022
Mild to Moderate Atopic Dermatitissource ↗
Past FDA Catalysts and PDUFA Decisions
How RKTO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RKTO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HT-001 | pruritus associated with skin toxicities caused by EGFR inhibitors | Phase 2a | 2025-04-15 | 50% reduction in pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21Read More | Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Linsley WayneDirector | Grant/Award | 75,000 75,000 held | $0.00 | 05/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RKTO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RKTO for Q2 2026. | ||||
Ownership Trends
RKTO Short Interest
Shares sold short, counted twice a month.
2.77%
Short % of Float
of tradable shares sold short
675.3K
Shares Sold Short
-8.1% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
288.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RKTO ranks across every disease it competes in
Competitive Position is a premium feature
See how RKTO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRKTO News
-RKTO
Nov 11, 2026▼ -7%today
Rocket One's Tracer Drone Secures Public Safety Wins Across Four Law Enforcement Agencies, Two Sheriff's Departments and Two Fire Departments
Rocket One Inc. announced that its subsidiary, Tracer Drone Technologies, has achieved public safety program wins across various law enforcement and fire departments. These wins include fleet additions and support for new unmanned aircraft systems programs. CEO Robb Knie highlighted the company's commitment to expanding drone capabilities and operational readiness for public safety agencies.
Read more →-RKTO
Nov 3, 2026Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients
Rocket One's subsidiary, Hoth Therapeutics, ended its Phase 2a trial of HT-001 early due to strong interim efficacy results. The company plans to seek FDA feedback for advancing HT-001 into a Phase 3 clinical program. HT-001 targets dermatologic toxicities linked to EGFR inhibitor cancer therapies, aiming to improve patient quality of life.
Read more →-RKTO
Oct 20, 2026▼ -6.6%on this news
Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Rocket One Inc. has entered a research agreement with Virginia Commonwealth University to develop magnetic computing devices aimed at enhancing AI capabilities while minimizing energy consumption. The one-year program will focus on creating straintronic magnetic tunnel junctions for next-generation AI chips, with potential applications in defense and space. The project aims to demonstrate ultra-low-power operations and improve computational accuracy in AI systems.
Read more →-RKTO
Oct 13, 2026▼ -6.7%on this news
Rocket One Signs Agreement to Advance Nanomagnetic AI Chip Technology and Device Prototyping
Rocket One Inc. has signed a research agreement with Virginia Commonwealth University to advance its SKYMRAM technology, which focuses on skyrmion-based magnetic memory for AI chips. The one-year program will begin on November 1, 2026, and aims to demonstrate critical proof-of-concept milestones. This initiative supports Rocket One's strategy in AI infrastructure, space, and defense computing.
Read more →-RKTO
Oct 6, 2026Rocket One Signs Patent License Agreement with U.S. Air Force for Technology Designed to Capture and Neutralize Hostile Drones
Rocket One Inc. has signed a patent license agreement with the U.S. Air Force for technology aimed at capturing hostile drones and isolating their communications. This 12-month evaluation license covers a patented system that could enhance security across various applications, including military bases and airports. The company plans to assess the technology's integration with its existing counter-UAS initiatives.
Read more →-RKTO
Sep 22, 2026Rocket One Signs Definitive Agreement to Acquire Revenue-Generating Tracer Drone Technologies, Accelerating AI and Counter-UAS Expansion Across Public Safety and Defense Markets
Rocket One has signed a definitive agreement to acquire Tracer Drone Technologies, which is expected to enhance its capabilities in AI and counter-UAS technologies. This acquisition aims to bolster Rocket One's presence in public safety and defense markets by adding a revenue-generating platform for drone sales, services, and training. The move could also create new commercial channels for advanced technologies.
Read more →-RKTO
Aug 24, 2026Rocket One Inc. to Attend IDGA’s Counter UAS Summit August 25 – 26, 2026
Rocket One Inc. announced that CEO Robb Knie will attend the IDGA Counter UAS Summit on August 25-26, 2026. The summit will take place at MGM Hotel and Casino in National Harbor, MD. Rocket One continues to advance its technologies in defense and space, including drone-swarm capabilities for counter-UAS training.
Read more →-RKTO
Aug 18, 2026Rocket One Launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS
Rocket One Inc. launched Swarm Stage AI, a drone-swarm threat-emulation platform for U.S. military and defense organizations. This technology enables realistic training scenarios to counter coordinated drone attacks. The platform adapts proven swarm coordination technology to enhance defense capabilities against unmanned aircraft threats. It aims to support the development of advanced counter-UAS technologies.
Read more →-RKTO
Aug 11, 2026Rocket One Accepted into Seagate Partner Program, Expanding AI Infrastructure and Enterprise Data Storage Ecosystem
Rocket One Inc. has been accepted into the Seagate Partner Program, gaining access to valuable resources for enterprise storage. This partnership aims to bolster Rocket One's strategy in AI infrastructure and advanced computing. The CEO highlighted the growing need for efficient data management as AI workloads increase.
Read more →-RKTO
Jul 30, 2026Rocket One and NASA Reach Agreement to Advance Space AI Technology
Rocket One Inc. has signed a nonexclusive patent license agreement with NASA for the Affordable Vehicle Avionics System. This technology will support Rocket One's AI-powered software platform for spacecraft mission planning and avionics modeling. The agreement aims to enhance engineering workflows for commercial and defense applications, positioning Rocket One for growth in the expanding space economy.
Read more →-RKTO
Jul 21, 2026Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing
Rocket One Inc. has announced a strategic partnership with Placeve to enhance its AI infrastructure platform. This collaboration aims to advance technologies in defense, space, and intelligent edge computing. The partnership includes an initial investment and a proposed commercial framework, with Placeve's AI processor technology currently being evaluated through NASA's MISSE program.
Read more →-RKTO
Jul 9, 2026▲ +13.4%on this news
Rocket One Adds SpaceXAI API to Its AI Technology Stack, Advancing Next-Generation Space and Defense Computing
Rocket One Inc. announced the integration of SpaceXAI's API into its AI technology stack. This addition enhances its capabilities in coding, reasoning, and various multimedia applications. The CEO emphasized the importance of advanced AI models for their strategy in defense and space technologies. The company aims to leverage these models for software development and intelligent data analysis.
Read more →-RKTO
Jun 24, 2026Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement
Rocket One Inc. has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by Nasdaq. The company's stock price remained above $1.00 for ten consecutive days. CEO Robb Knie expressed satisfaction with this milestone, emphasizing their focus on advanced AI computing and defense technologies. The company aims to enhance shareholder value through strategic growth initiatives.
Read more →-RKTO
Jun 22, 2026▼ -6.5%on this news· ran to -19% by day 3shared move
Rocket One Launches Swarm Stage AI(TM) to Counter Autonomous Drone Swarms
Rocket One Inc. has launched Swarm Stage AI™, an autonomous swarm simulation platform aimed at countering drone threats. This technology, derived from SkyStage's assets, will assist military and security organizations in training against coordinated drone attacks. The platform is expected to enhance defense readiness and support future space security missions.
Read more →-RKTO
Jun 15, 2026▼ -7.6%on this news
Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
Rocket One, Inc. reported approximately $8.4 million in cash and cash equivalents. The company outlined its strategic focus on advanced computing technologies, particularly in AI infrastructure and spintronic computing for space and defense markets. This update aims to inform shareholders about the company's financial health and future direction.
Read more →-RKTO
Jun 11, 2026▲ +11.3%on this newsshared move
Rocket One Announces Former NASA Astronaut and International Space Station Commander Shane Kimbrough to Join Rocket One Space Advisory Board
Rocket One, Inc. has appointed Colonel (Ret.) Shane Kimbrough, a former NASA astronaut, to its Space Advisory Board. Kimbrough's extensive experience in space missions and technology development will guide Rocket One's strategy in advanced computing and orbital technology. The company aims to enhance its capabilities in the growing space economy.
Read more →-RKTO
Jun 9, 2026▼ -7.9%on this news· ran to -20% by day 3shared move
Rocket One To File Patent Applications for AI-Powered Autonomous Defense and Space Security Platform Designed to Protect the Infrastructure of the Future
Rocket One Inc. announced plans to file provisional patents for an AI-powered defense platform aimed at protecting critical infrastructure and space systems. The technology focuses on counter-drone threats and autonomous security measures. CEO Robb Knie emphasized the importance of AI and advanced computing in addressing modern security challenges. The company aims to expand its intellectual property in this field.
Read more →-RKTO
Jun 3, 2026ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD
Rocket One, Inc. appointed Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board. With nearly four decades of military and national security experience, Frost will support the company's expansion into AI infrastructure for space and defense applications. His expertise in strategic operations is expected to enhance Rocket One's long-term strategy.
Read more →-RKTO
Jun 3, 2026Adelina: 4702663 ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD Former U.S. Army Major General Brings Decades of National Security, Strategic Operations, and Defense Leaders
Rocket One, Inc. has appointed Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board. General Frost brings extensive experience in military operations and strategic planning from his nearly four-decade-long career in the U.S. Army. His appointment is expected to enhance Rocket One's development of advanced computing technologies aimed at addressing national security needs. The company is focused on creating technologies for space and defense applications while navigating significant challenges related to funding and market competition.
Read more →-RKTO
Jun 1, 2026▼ -8.2%on this news· ran to +52% by day 1shared move
Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
Rocket One Inc. has appointed Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for its AI nanomagnetic technology. His role is pivotal in advancing the company's development of radiation-tolerant AI chip platforms designed for space and defense applications. With his extensive expertise in nanomagnetics, Dr. Bandyopadhyay aims to translate foundational research into practical and deployable systems. This strategic appointment marks a significant transition for Rocket One as it shifts focus from launch technologies to computing solutions suitable for harsh environmental conditions.
Read more →About Rocket One Inc.
Headquarters720 MONROE STREET, HOBOKEN, NJ, 07030
BIOPHARMAWATCH ELITE
Trade the next RKTO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime